by GOAI

由GOAI生成

Share To

分享到

Innovent Biologics has obtained approval from China’s National Medical Products Administration (NMPA) for its New Drug Application (NDA) for Tabosun, a monoclonal antibody targeting CTLA-4. The drug is intended for the treatment of colon cancer, marking a significant regulatory milestone for the company..

信达生物已获得中国国家药品监督管理局（NMPA）对其针对CTLA-4的单克隆抗体药物Tabosun的新药申请（NDA）的批准。该药物用于治疗结肠癌，标志着该公司在监管方面取得了重要的里程碑。

Tabosun is designed to address colon cancer by targeting CTLA-4, a protein involved in immune system regulation. The approval follows Innovent’s submission of clinical data supporting the drug’s efficacy and safety profile. This development allows Innovent to proceed with plans to make Tabosun available as a treatment option for patients diagnosed with colon cancer in China..

Tabosun旨在通过靶向CTLA-4这种参与免疫系统调节的蛋白质来应对结肠癌。此次批准是基于信达生物提交的临床数据，证明了该药物的有效性和安全性。这一进展使信达生物能够推进计划，将Tabosun作为治疗选项提供给中国确诊的结肠癌患者。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

For any suggestion and feedback, please contact us.

如有任何建议和反馈，请联系我们。

Date: December 29, 2025

日期：2025年12月29日

Related posts:

相关文章：

Phase 3 Trial Evaluates Imetelstat for Myelofibrosis Patients Resistant to JAK Inhibitors

第三阶段试验评估了对JAK抑制剂耐药的骨髓纤维化患者的Imetelstat疗效

New Research Explores Restoring Breathing Function in Spinal Cord Injury Patients

新研究探讨恢复脊髓损伤患者的呼吸功能

Radiopharmaceuticals Target Cancer Cells While Minimizing Damage to Healthy Tissue

放射性药物靶向癌细胞同时尽量减少对健康组织的损害

Study Links TUBB Gene Mutations to Disrupted Ciliogenesis and Ciliopathy Symptoms

研究将TUBB基因突变与纤毛生成中断及纤毛病症状联系起来

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

GOAI

GOAI

Related Post

相关文章

News Flash

新闻快讯

India’s Pharmaceutical Industry Shifts Focus to Innovation and Global Partnerships Ahead of 2026

印度制药行业在2026年前将重点转向创新和全球合作

2025-12-29

2025年12月29日